Please login to the form below
Trump administration
This page shows the latest Trump administration news and features for those working in and with pharma, biotech and healthcare.
Pfizer, Sanofi and others set to increase US drug prices in 2021
Soaring drug prices had been a key issue for the Trump administration, with the outgoing US president issuing several executive orders in late 2020 aimed at lowering prices.
Latest news
-
Gavi says 76 wealthy countries have committed to COVAX vaccine facility
donations. Earlier this week, the US said it would not join the facility because of the Trump administration’s objection to the WHO’s involvement.
-
American Medical Association calls for COVID-19 vaccine development transparency
Organisation asks FDA to provide transparent information on review plans. The American Medical Association (AMA) has urged the US Food and Drug Administration (FDA) to work with the medical community to ... The Trump administration-backed Operation Warp
-
US payments for COVID-19 vaccines tied to specific timing milestones
Information from public documents and a Trump administration official reveals that the US government is tying certain payments for potential COVID-19 vaccines to specific timing goals, linked with production and
-
COVID-19 vaccine approval unlikely before November, says US NIH director
The Trump administration-backed Operation Warp Speed initiative aims to deliver 300 million doses of a COVID-19 vaccine to the American public by January 2021. ... Last week, President Donald Trump announced that it was possible a coronavirus vaccine
-
UK, China prep trials of coronavirus vaccine candidates
Other companies with vaccines in development include CureVac – which was forced to deny allegations it had been offered $1bn to relocate to the US by the Trump administration – and Pfizer/BioNTech.
More from news
Approximately 2 fully matching, plus 36 partially matching documents found.
Latest Intelligence
-
Eliminating pharmaceutical rebates, is this déjà vu?
In July 2020, the Trump administration announced its intention, for the second time, to prohibit rebates for Medicare Part D drugs within PBMs as one of several new Executive Orders aimed ... We propose that the administration requires setting patient
-
Will biosimilars ever catch on in the US?
In the early days of the Trump administration, then-FDA commissioner Scott Gottlieb made a point of clearing the way for even faster and more generic approvals, again with some apparent
-
The Golden Goose
When efforts by the Trump administration to repeal and replace Obamacare lost momentum, it shifted to reducing drug costs. ... Another question: how serious is Trump about confronting this problem? His administration has floated several cost reduction
-
The handover: Pfizer reshapes itself for a new era
This was because Read had agreed to reverse previously announced price increases after being telephoned by President Trump in July. ... The Trump administration has also just floated the idea of pegging US (Medicare part B) drug prices to other countries,
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
